HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
Sign Up to like & getrecommendations! Published in 2018 at "BMB Reports"
DOI: 10.5483/bmbrep.2018.51.12.259
Abstract: Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers. However, as with other targeted therapies, intrinsic or acquired resistance to HER2 inhibitors… read more here.
Keywords: her2 positive; gastric cancer; lapatinib resistant; intrinsic acquired ... See more keywords